About Us
We are at a breakthrough moment for Alzheimer’s disease research and drug development. At Acumen, we are leveraging decades of learnings to deliver treatments that can truly impact everyone affected by this devastating disease. Alzheimer’s disease is currently estimated to affect approximately seven million people in the United States and 55 million people worldwide. Due to the aging population, patient populations in the United States impacted by AD are expected to grow to approximately 13 million people by 2050 without effective preventative measures or safe and effective disease-modifying treatments. By 2050, healthcare costs for AD in the United States alone are estimated to near $1 trillion.